Related references
Note: Only part of the references are listed.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents
Mark Agulnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
A Lipton et al.
CANCER (2005)
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
MC Gutierrez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Impact of metastatic estrogen receptor and progesterone receptor status on survival
EE Lower et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers
S Kurbel
MEDICAL HYPOTHESES (2005)
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas
P Regitnig et al.
JOURNAL OF PATHOLOGY (2004)
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems
A Rhodes et al.
JOURNAL OF CLINICAL PATHOLOGY (2000)
Share Paper
